Philippe Moreau, MD, on Results With Daratumumab Plus VTd in Newly Diagnosed Myeloma at ASCO 2021

Video

Moreau detailed the patient characteristics of those enrolled on the CASSIOPEIA trial, which investigating bortezomib, thalidomide and dexamethasone plus daratumumab in patients with newly diagnosed multiple myeloma.

Philippe Moreau, MD, of the University Hospital of Nantes, spoke with CancerNetwork® at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, details results from part 2 of the phase 3 CASSIOPEIA trial (NCT02541383), which utilized daratumumab (Darzalex) maintenance following bortezomib, thalidomide and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma.

Transcription:

In part 2, we were able to randomize 886 patients—442 [to] daratumumab maintenance [for] 2 years and 444 for observation. In fact, the patient characteristics were well balanced [between] the 2 groups. Of note, 76.2% of those in the daratumumab arm and 75.9% of those in the observation arm were MRD negative at the time of the second randomization. The study met its primary end point, indicating that daratumumab is significantly improving progression-free survival from second randomization versus observation with a hazard ratio of 0.53. [However], when we looked at the subgroup analysis and pre-specified subgroup analysis, we saw that the benefit of daratumumab maintenance was observed only in patients who did not receive daratumumab up front. Patients who only received VTd up front benefited from daratumumab maintenance. That is a very important finding.

Reference

Moreau P, Sonneveld P. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. J Clin Oncol. 2021;39(suppl 15):8004. doi:10.1200/JCO.2021.39.15_suppl.8004

Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content